Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mazdutide first-in-human study
NCT02972645Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2016
- Primary completion
- Jul 2017
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and type 2 diabetes mellitus (T2DM) comparing Mazdutide with Placebo (2 arms). Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) considered by the Investigator to be Related to Study Drug Administration at 16 weeks. Started Dec 2016; status: completed.
02
Drugs
mazdutide
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02972645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02972645.